2022 Fiscal Year Final Research Report
Glycan expression profile of schirrhous gastric cancer
| Project/Area Number |
20K09097
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 55020:Digestive surgery-related
|
|---|
| Research Institution | University of Tsukuba |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
小田 竜也 筑波大学, 医学医療系, 教授 (20282353)
下村 治 筑波大学, 医学医療系, 講師 (60808070)
|
|---|
| Project Period (FY) |
2020-04-01 – 2023-03-31
|
| Keywords | スキルス胃癌 / 糖鎖 / レクチン / rBC2LCN / シアリル化糖鎖 / 薬物治療 |
|---|
| Outline of Final Research Achievements |
Schirrhous type of gastric cancer is classified as a genomic stable (GS) subtype with few genetic alterations in a comprehensive large-scale whole genome analysis, and has a poor prognosis due to the lack of efficacy targeting drugs that target membrane proteins on the surface of cancer cells and tumor immunostimulating therapy. In this study, we focused on carbohydrate chains in the outermost layer of cancer cells and identified 11 lectins with high affinity to scirrhous gastric cancer cells and 8 lectins with low affinity by comprehensive lectin microarray. Among the high-affinity lectins, the rBC2LCN lectin can be administered to living animals and showed anti-tumor effects in murine scirrhous gastric cancer models by using a lectin-drug complex, indicating the possibility of sugar chain-targeted drug therapy.
|
| Free Research Field |
腫瘍学
|
| Academic Significance and Societal Importance of the Research Achievements |
未だ有効な薬物治療がなく予後が不良なスキルス胃癌に対して、従来の薬剤とは異なるがん細胞表面糖鎖を標的とした新規薬物治療が、有効である可能性を示すことができた。膵癌に対する先行研究を元に臨床応用に向けたレクチン薬物複合体の製剤開発が進んでおり、将来的にスキルス胃癌に対して新たな治療オプションとなる可能性があり、その治療成績を向上させることができるかもしれない。
|
